Concepts (171)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| ErbB Receptors | 6 | 2014 | 492 | 1.840 |
Why?
|
| src Homology Domains | 6 | 2017 | 44 | 1.740 |
Why?
|
| Protein Array Analysis | 6 | 2017 | 50 | 1.100 |
Why?
|
| Proteins | 4 | 2017 | 784 | 1.070 |
Why?
|
| Protein Interaction Mapping | 3 | 2017 | 82 | 1.010 |
Why?
|
| Signal Transduction | 8 | 2015 | 3327 | 0.920 |
Why?
|
| Proteome | 4 | 2015 | 127 | 0.840 |
Why?
|
| Blotting, Western | 2 | 2017 | 793 | 0.830 |
Why?
|
| Protein Interaction Domains and Motifs | 1 | 2017 | 86 | 0.570 |
Why?
|
| Fluorescence Polarization | 2 | 2014 | 9 | 0.560 |
Why?
|
| Quantitative Trait Loci | 3 | 2014 | 601 | 0.530 |
Why?
|
| Proteomics | 3 | 2017 | 221 | 0.510 |
Why?
|
| Proto-Oncogene Proteins c-kit | 1 | 2014 | 80 | 0.470 |
Why?
|
| Receptors, Androgen | 1 | 2014 | 118 | 0.460 |
Why?
|
| Phenylethyl Alcohol | 1 | 2012 | 1 | 0.430 |
Why?
|
| Caffeic Acids | 1 | 2012 | 5 | 0.430 |
Why?
|
| Oncogene Protein v-akt | 1 | 2012 | 21 | 0.420 |
Why?
|
| Proto-Oncogene Proteins c-met | 1 | 2014 | 199 | 0.420 |
Why?
|
| Ribosomal Protein S6 Kinases, 70-kDa | 1 | 2012 | 44 | 0.420 |
Why?
|
| Mass Spectrometry | 1 | 2011 | 189 | 0.380 |
Why?
|
| Receptor, ErbB-2 | 1 | 2012 | 234 | 0.380 |
Why?
|
| Phosphorylation | 5 | 2014 | 1121 | 0.350 |
Why?
|
| RNA, Messenger | 2 | 2014 | 1994 | 0.340 |
Why?
|
| Cell Proliferation | 3 | 2012 | 1621 | 0.340 |
Why?
|
| Carcinoma | 1 | 2012 | 440 | 0.320 |
Why?
|
| Transcription Factors | 3 | 2014 | 1619 | 0.310 |
Why?
|
| Protein Binding | 5 | 2014 | 1475 | 0.250 |
Why?
|
| Cell Line, Tumor | 6 | 2017 | 2500 | 0.200 |
Why?
|
| Phosphotyrosine | 2 | 2014 | 33 | 0.190 |
Why?
|
| Prostatic Neoplasms | 1 | 2012 | 1753 | 0.190 |
Why?
|
| Systems Biology | 2 | 2011 | 43 | 0.190 |
Why?
|
| gag Gene Products, Human Immunodeficiency Virus | 1 | 2020 | 2 | 0.180 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2020 | 66 | 0.180 |
Why?
|
| Phosphopeptides | 2 | 2012 | 11 | 0.180 |
Why?
|
| Surface Plasmon Resonance | 2 | 2012 | 47 | 0.180 |
Why?
|
| Rhodopseudomonas | 2 | 1989 | 51 | 0.170 |
Why?
|
| Nitrogen Fixation | 2 | 1989 | 37 | 0.170 |
Why?
|
| Genetic Variation | 3 | 2014 | 1365 | 0.160 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2020 | 164 | 0.160 |
Why?
|
| Genes, Bacterial | 2 | 1989 | 198 | 0.160 |
Why?
|
| Cisplatin | 2 | 2017 | 614 | 0.150 |
Why?
|
| Genome-Wide Association Study | 3 | 2014 | 1648 | 0.140 |
Why?
|
| Humans | 16 | 2020 | 87555 | 0.140 |
Why?
|
| Cell Line | 2 | 2014 | 2488 | 0.140 |
Why?
|
| Computational Biology | 2 | 2011 | 534 | 0.130 |
Why?
|
| Base Sequence | 4 | 2014 | 2331 | 0.130 |
Why?
|
| Genome, Human | 3 | 2014 | 766 | 0.130 |
Why?
|
| Amino Acid Sequence | 5 | 2010 | 2061 | 0.120 |
Why?
|
| Breast Neoplasms | 1 | 2008 | 2961 | 0.120 |
Why?
|
| Phosphoproteins | 1 | 2015 | 257 | 0.120 |
Why?
|
| Tyrosine | 1 | 2014 | 133 | 0.120 |
Why?
|
| Toll-Like Receptors | 2 | 2011 | 92 | 0.120 |
Why?
|
| Animals | 9 | 2017 | 26951 | 0.120 |
Why?
|
| Neoplasms, Experimental | 1 | 2015 | 269 | 0.110 |
Why?
|
| Chromosome Mapping | 2 | 2014 | 1076 | 0.110 |
Why?
|
| Mice, Nude | 2 | 2012 | 809 | 0.110 |
Why?
|
| RNA Interference | 1 | 2014 | 372 | 0.110 |
Why?
|
| Molecular Targeted Therapy | 1 | 2015 | 278 | 0.110 |
Why?
|
| Transcriptome | 2 | 2014 | 609 | 0.110 |
Why?
|
| Chromatography, Gel | 1 | 2012 | 103 | 0.110 |
Why?
|
| Genotype | 2 | 2014 | 1862 | 0.110 |
Why?
|
| Cytotoxins | 1 | 2012 | 16 | 0.110 |
Why?
|
| RNA, Small Interfering | 1 | 2014 | 554 | 0.110 |
Why?
|
| Antibodies | 1 | 2014 | 353 | 0.110 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2014 | 308 | 0.100 |
Why?
|
| Pharmacogenetics | 2 | 2014 | 440 | 0.100 |
Why?
|
| Neoplasm Proteins | 1 | 2015 | 539 | 0.100 |
Why?
|
| Cell Physiological Phenomena | 1 | 2011 | 24 | 0.100 |
Why?
|
| Models, Genetic | 2 | 2014 | 937 | 0.100 |
Why?
|
| Binding Sites | 1 | 2014 | 1107 | 0.100 |
Why?
|
| DNA, Bacterial | 2 | 1989 | 237 | 0.100 |
Why?
|
| Viruses | 1 | 2011 | 78 | 0.100 |
Why?
|
| Sequence Analysis, DNA | 1 | 2014 | 860 | 0.100 |
Why?
|
| HIV Infections | 1 | 2020 | 824 | 0.090 |
Why?
|
| Gene Expression Regulation | 2 | 2017 | 1956 | 0.090 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2012 | 465 | 0.090 |
Why?
|
| Oncogene Proteins v-abl | 1 | 2010 | 2 | 0.090 |
Why?
|
| Down-Regulation | 1 | 2012 | 512 | 0.090 |
Why?
|
| Gene Expression | 1 | 2014 | 1296 | 0.090 |
Why?
|
| Transfer RNA Aminoacylation | 1 | 2009 | 18 | 0.090 |
Why?
|
| Equipment Failure Analysis | 1 | 2010 | 90 | 0.090 |
Why?
|
| Sirolimus | 1 | 2011 | 171 | 0.090 |
Why?
|
| Mice, Inbred BALB C | 1 | 2012 | 1073 | 0.090 |
Why?
|
| Methionine | 1 | 2009 | 66 | 0.090 |
Why?
|
| Gene Expression Profiling | 1 | 2015 | 1412 | 0.090 |
Why?
|
| Antineoplastic Agents | 3 | 2017 | 2384 | 0.080 |
Why?
|
| Indoles | 1 | 2011 | 307 | 0.080 |
Why?
|
| Equipment Design | 1 | 2010 | 411 | 0.080 |
Why?
|
| Receptor, ErbB-4 | 1 | 2008 | 5 | 0.080 |
Why?
|
| DNA-Binding Proteins | 1 | 2014 | 1224 | 0.080 |
Why?
|
| Dendritic Cells | 1 | 2011 | 434 | 0.080 |
Why?
|
| Software | 2 | 2015 | 657 | 0.070 |
Why?
|
| Algorithms | 1 | 2015 | 1849 | 0.070 |
Why?
|
| Peptides | 1 | 2010 | 644 | 0.070 |
Why?
|
| Oxidative Stress | 1 | 2009 | 453 | 0.070 |
Why?
|
| Breast | 1 | 2008 | 289 | 0.070 |
Why?
|
| Immunity, Innate | 1 | 2009 | 424 | 0.070 |
Why?
|
| Mice | 4 | 2012 | 11586 | 0.070 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2014 | 2385 | 0.070 |
Why?
|
| Molecular Sequence Data | 5 | 2010 | 3028 | 0.070 |
Why?
|
| Sensitivity and Specificity | 1 | 2010 | 2016 | 0.060 |
Why?
|
| Heart | 1 | 2008 | 567 | 0.060 |
Why?
|
| Peptide Fragments | 2 | 2005 | 459 | 0.060 |
Why?
|
| Magnesium Chloride | 1 | 2004 | 5 | 0.060 |
Why?
|
| Drug Synergism | 2 | 2017 | 303 | 0.060 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2011 | 1089 | 0.060 |
Why?
|
| Protein Structure, Tertiary | 1 | 2005 | 738 | 0.060 |
Why?
|
| Head and Neck Neoplasms | 1 | 2011 | 1057 | 0.060 |
Why?
|
| Antibodies, Monoclonal | 1 | 2010 | 1393 | 0.060 |
Why?
|
| Fibroblast Growth Factors | 1 | 2004 | 81 | 0.060 |
Why?
|
| Reproducibility of Results | 1 | 2010 | 2734 | 0.060 |
Why?
|
| Prognosis | 1 | 2008 | 3708 | 0.050 |
Why?
|
| Genomics | 1 | 2005 | 737 | 0.040 |
Why?
|
| Biomarkers, Tumor | 1 | 2008 | 1505 | 0.040 |
Why?
|
| Viral Load | 1 | 2020 | 151 | 0.040 |
Why?
|
| Tribolium | 1 | 1997 | 9 | 0.040 |
Why?
|
| Brain | 1 | 2008 | 2245 | 0.040 |
Why?
|
| Anti-HIV Agents | 1 | 2020 | 155 | 0.040 |
Why?
|
| Lymphocyte Activation | 1 | 2020 | 737 | 0.040 |
Why?
|
| Hybridization, Genetic | 1 | 1997 | 106 | 0.040 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2020 | 436 | 0.040 |
Why?
|
| Phenotype | 2 | 2014 | 2415 | 0.040 |
Why?
|
| Apoptosis | 2 | 2014 | 1703 | 0.030 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2020 | 582 | 0.030 |
Why?
|
| Male | 3 | 2020 | 41502 | 0.030 |
Why?
|
| Drug Design | 1 | 2015 | 124 | 0.030 |
Why?
|
| HapMap Project | 1 | 2014 | 47 | 0.030 |
Why?
|
| Paclitaxel | 1 | 2014 | 475 | 0.030 |
Why?
|
| Interferon Regulatory Factor-3 | 1 | 2011 | 13 | 0.030 |
Why?
|
| Interferons | 1 | 2011 | 134 | 0.020 |
Why?
|
| In Situ Nick-End Labeling | 1 | 2011 | 122 | 0.020 |
Why?
|
| Sequence Analysis | 1 | 2010 | 26 | 0.020 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2011 | 114 | 0.020 |
Why?
|
| Microarray Analysis | 1 | 2010 | 96 | 0.020 |
Why?
|
| Neoplasm Transplantation | 1 | 2011 | 396 | 0.020 |
Why?
|
| MAP Kinase Signaling System | 1 | 2011 | 195 | 0.020 |
Why?
|
| RNA, Transfer, Met | 1 | 2009 | 6 | 0.020 |
Why?
|
| Genetic Code | 1 | 2009 | 25 | 0.020 |
Why?
|
| Orthomyxoviridae | 1 | 2009 | 37 | 0.020 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2011 | 184 | 0.020 |
Why?
|
| Sequence Alignment | 1 | 2010 | 353 | 0.020 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 2010 | 416 | 0.020 |
Why?
|
| Cluster Analysis | 1 | 2010 | 369 | 0.020 |
Why?
|
| NADPH Oxidases | 1 | 2009 | 82 | 0.020 |
Why?
|
| Tumor Cells, Cultured | 1 | 2011 | 1048 | 0.020 |
Why?
|
| Substrate Specificity | 1 | 2009 | 350 | 0.020 |
Why?
|
| Neovascularization, Pathologic | 1 | 2011 | 364 | 0.020 |
Why?
|
| Cell Survival | 1 | 2011 | 977 | 0.020 |
Why?
|
| HeLa Cells | 1 | 2009 | 503 | 0.020 |
Why?
|
| Female | 4 | 2020 | 45191 | 0.020 |
Why?
|
| Adenoviridae | 1 | 2009 | 347 | 0.020 |
Why?
|
| Ligands | 1 | 2009 | 437 | 0.020 |
Why?
|
| Ribosomal Proteins | 1 | 1987 | 45 | 0.020 |
Why?
|
| Reactive Oxygen Species | 1 | 2009 | 482 | 0.020 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2011 | 597 | 0.020 |
Why?
|
| Models, Molecular | 1 | 2010 | 1290 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 1 | 2011 | 3161 | 0.020 |
Why?
|
| Fibroblast Growth Factor 7 | 1 | 2004 | 10 | 0.020 |
Why?
|
| Culture Media | 1 | 2004 | 147 | 0.010 |
Why?
|
| Heparin | 1 | 2004 | 184 | 0.010 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2004 | 562 | 0.010 |
Why?
|
| Escherichia coli | 1 | 2004 | 601 | 0.010 |
Why?
|
| Middle Aged | 1 | 2020 | 25343 | 0.010 |
Why?
|
| Adult | 1 | 2020 | 26018 | 0.010 |
Why?
|
| Sexual Behavior, Animal | 1 | 1997 | 92 | 0.010 |
Why?
|
| Models, Biological | 1 | 2004 | 1759 | 0.010 |
Why?
|
| Sequence Homology, Nucleic Acid | 1 | 1987 | 173 | 0.000 |
Why?
|
| Species Specificity | 1 | 1987 | 682 | 0.000 |
Why?
|
| Saccharomyces cerevisiae | 1 | 1987 | 435 | 0.000 |
Why?
|
| DNA | 1 | 1987 | 1305 | 0.000 |
Why?
|
| Rats | 1 | 1987 | 4013 | 0.000 |
Why?
|